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Rafal T. Marszalek* and Louisa FlintoftBox 1. Open Source Definition and “fields of
endeavour”
One of the open source code criteria, according to the Open
Source Definition, is no discrimination against fields of endeavor.
What this means in practice is that tools released under
OSI-compliant licenses cannot use the “for non-commercial
use only” disclaimers. A common worry [9] is that this affects
whether the tool can be commercialized:
Do open source licenses stop me from commercializing my
code?
No – no matter which open source license is used.
Do open source licenses mean that others can commercialize
my code?Fifteen years ago Genome Biology published its first Soft-
ware article [1]. It described a suite of programs for the
analysis of microarray data. The tool was deposited on
the authors’ website (now defunct) and was “copyrighted
against commercial gain”. The conditions of deposition
and release reflected the understanding of and the reser-
vations about open source that the scientific community
had at the beginning of this century.
Many readers will be aware that this would not stand
today: the times have changed, the field has matured,
and the definition of open science has crystallized. Many
researchers now acknowledge that openness and trans-
parency foster better, reproducible research. A Comment
published in our journal last year argued that all re-
search should be carried out openly, so that what we
today call ‘open science’ should just become ‘science’ [2].
One recent study also showed that, despite common
misconceptions, open science can actually aid researchers’
careers [3].
With all the benefits that open science brings, our
authors and readers could not have been surprised in
the past several years to see us require that any source
code published as a part of an article is deposited in a
recognized public source code repository [4]. Since the
beginning of 2016 we have also started requesting
that the authors of Method and Software articles de-
scribing new computational tools archive the version
used in the manuscript in a DOI-assigning repository,
such as Figshare [5] or Zenodo [6]. This way the re-
searchers trying to reproduce analyses described in
the article can use the exactly same code as the authors -
inoculating those analyses against the inevitable evolution
of code.
We consider source code availability and accessibility
to be important to ensure that computational analyses
can be easily repeated and research shown to be repro-
ducible. It is, however, no less critical that the source* Correspondence: editorial@genomebiology.com
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research: that other people can use it, and develop it,
and build on it (and cite it [7]), and create new and
wonderful tools that the authors of the original may
not have even dreamed of. And an important factor
affecting the ability to do this is the source code
license.
This is why Genome Biology requires that the source
code published as a part of an article is released under a
license complying with an Open Source Definition, as
defined by the Open Source Initiative [8]. This means
that the source code can be used, modified, and distrib-
uted by anyone (importantly, the definition assures no
discrimination against fields of endeavor; for more see
Box). We believe that, together with a robust source
code archiving strategy, employing open source licenses
serves to preserve the source code long-term — through
its re-use, re-purposing, and further evolution. And thus
it really helps it become a foundation of research not yet
imagined.By definition, the open source code can be commercialized by
anyone: the code’s author, their institution, an independent
commercial entity, a private person. Literally anyone. This is
independent of the exact OSI-compliant license used.
le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
How do I choose a license?
The good folks of Github came to the rescue and created the
‘Choose an open source license’ service [10] for this. You can
also browse for an appropriate license on the Open Source
Initiative website [8]. Although some users believe that open
source code should never be released under licenses that
are “copyleft” [11] (these are the licenses which require that
any derivative of the code is released under the same
license), an equally good argument can be made [12] for
GPL license-compatible licenses (which often are “copyleft”).
While the use of permissive licenses that are not “copyleft” is
more in the spirit of open science, Genome Biology currently
accepts all OSI-compliant licenses.
How do I go about licensing my source code from the legal
point of view?
Only the owner of the intellectual property rights to the source
code can license it. While Genome Biology requires that the
source code is released under an OSI-compliant license, it is the
authors’ responsibility to ensure that they are within their rights
to use such a license in the first place. Morin and colleagues
provide a handy guide for the authors on what to do before
you release your code under any license [13].
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